Business
Shield Therapeutics (STX): Reassessing the US o...
Shield Therapeutics (STX): Reassessing the US o....
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \n\n\nHardman & Co Research\n\n\n\nHardman & Co Research: Shield Therapeutics (STX): Reassessing the US opportunity06-Jan-2021 / 07:15 GMT/BST\n\n\nHardman & Co Research: Reassessing the US opportunity\n\nSTX is a commercial-stage company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru(R)/Accrufer(R) has been approved by the regulators in both Europe and the US. For various reasons, STX has been unable to secure a commercial partner for Accrufer in the US. Consequently, the board is now considering an STX-led launch option, thereby retaining all the US profits. Financial modelling shows the logic of this option, but it would necessitate financing the working capital requirements covering the next two years in the region of £25m-£30m.\n\nPlease click on the link below for the full report\n\nhttps://www.hardmanandco.com/research/corporate-research/reassessing-the-us-opportunity/ \n\nIf you are interested in meeting the company, you can register your interest by clicking on the above link\n\n\n To contact us:\n\n Hardman & Co1 Frederick's Place\n\n London\n\n EC2R 8AE\n\n www.hardmanandco.com\n\n Follow us on Twitter @HardmanandCo\n \n \n Contact:\n\n Dr Martin Hall\n\n +44 (0) 20 3692 7075\n \n \n \n\n [email protected] \n \n Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.\n\nAbout Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case. \n\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Lt...